The Centers for Disease Control and Prevention released a ‘Dear Colleague’ letter regarding the U.S. Food and Drug Administration’s Drug Safety Communication on the potential risk of antiretroviral medication dolutegravir (DTG) associated neural tube birth defects. Read the letter.

Go to Original Post